<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pharmacol</journal-id><journal-title>BMC Pharmacology</journal-title><issn pub-type="epub">1471-2210</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2210-4-23</article-id><article-id pub-id-type="pmid">15491498</article-id><article-id pub-id-type="doi">10.1186/1471-2210-4-23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Yang</surname><given-names>Baichun</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>baichun.w.yang@gsk.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Brown</surname><given-names>Kathleen K</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Kathleen.K.Brown@gsk.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Chen</surname><given-names>Lihong</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Lihong.Z.Chen@GSK.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Carrick</surname><given-names>Kevin M</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Kevin.M.Carrick@GSK.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Clifton</surname><given-names>Lisa G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Lisa.G.clifton@gsk.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>McNulty</surname><given-names>Judi A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Judi.A.McNulty@gsk.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Winegar</surname><given-names>Deborah A</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Debbie.A.winegar@gsk.com</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Strum</surname><given-names>Jay C</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Jay.c.strum@gsk.com</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Stimpson</surname><given-names>Stephen A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Stephen.A.Stimpson@GSK.com</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Pahel</surname><given-names>Gregory L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Greg.L.Pahel@gsk.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Departments of Molecular Pharmacology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA</aff><aff id="I2"><label>2</label>Metabolic Diseases, GlaxoSmithKline, Research Triangle Park, NC 27709, USA</aff><aff id="I3"><label>3</label>Quantitative Expression, GlaxoSmithKline, Research Triangle Park, NC 27709, USA</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>18</day><month>10</month><year>2004</year></pub-date><volume>4</volume><fpage>23</fpage><lpage>23</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2210/4/23"/><history><date date-type="received"><day>18</day><month>6</month><year>2004</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Yang et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Yang et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Yang Baichun baichun.w.yang@gsk.com </dc:author><dc:title> Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>BMC Pharmacology 4(1): 23-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2210(2004)4:1&#x0003c;23&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2210</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>PPAR&#x003b3; agonists ameliorate insulin resistance and dyslipidemia in type 2 diabetic patients. Adiponectin possesses insulin sensitizing properties, and predicts insulin sensitivity of both glucose and lipid metabolism. In diet-induced insulin resistant rats and ZDF rats, the current studies determined the correlation between PPAR&#x003b3; agonist-upregulated fatty acid binding protein(FABP3) mRNA in adipose tissue and PPAR&#x003b3; agonist-elevated serum adiponectin, and the correlation between PPAR&#x003b3; agonist-elevated serum adiponectin and PPAR&#x003b3; agonist-mediated efficacy in insulin sensitization and lipid lowering.</p></sec><sec><title>Results</title><p>Parallel groups of SD rats were fed a high fat/sucrose (HF) diet for 4 weeks. These rats were orally treated for the later 2 weeks with vehicle, either PPAR&#x003b3; agonist GI262570 (0.2&#x02013;100 mg/kg, Q.D.), or GW347845 (3 mg/kg, B.I.D). Rats on HF diet showed significant increases in postprandial serum triglycerides, free fatty acids (FFA), insulin, and area under curve (AUC) of serum insulin during an oral glucose tolerance test, but showed no change in serum glucose, adiponectin, and glucose AUC. Treatment with GI262570 dose-dependently upregulated adipose FABP3 mRNA, and increased serum adiponectin. There was a positive correlation between adipose FABP3 mRNA and serum adiponectin (r = 0.7350, p &#x0003c; 0.01). GI262570 dose-dependently decreased the diet-induced elevations in triglycerides, FFA, insulin, and insulin AUC. Treatment with GW347845 had similar effects on serum adiponectin and the diet-induced elevations. There were negative correlations for adiponectin versus triglycerides, FFA, insulin, and insulin AUC (For GI262570, r = -0.7486, -0.4581, -0.4379, and -0.3258 respectively, all p &#x0003c; 0.05. For GW347845, r = -0.6370, -0.6877, -0.5512, and -0.3812 respectively, all p &#x0003c; 0.05). In ZDF rats treated with PPAR&#x003b3; agonists pioglitazone (3&#x02013;30 mg/kg, B.I.D.) or GW347845 (3 mg/kg, B.I.D.), there were also negative correlations for serum adiponectin versus glucose, triglycerides, FFA (for pioglitazone, r = -0.7005, -0.8603, and -0.9288 respectively; for GW347845, r = -0.9721, -0.8483, and -0.9453 respectively, all p &#x0003c; 0.01).</p></sec><sec><title>Conclusions</title><p>This study demonstrated that (a) PPAR&#x003b3; agonists improved insulin sensitivity and ameliorated dyslipidemia in HF fed rats and ZDF rats, which were correlated with serum adiponectin; (b) Serum adiponectin was positively correlated with adipose FABP3 mRNA in GI262570-treated rats. These data suggest that serum adiponectin can serve as a biomarker for both <italic>in vivo </italic>PPAR&#x003b3; activation and PPAR&#x003b3; agonist-induced efficacy on insulin resistance and dyslipidemia in rats.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Type 2 diabetes mellitus (T2D) and the metabolic syndrome are characterized by resistance to the action of insulin in peripheral tissues, including skeletal muscle, liver, and adipose. Activation of the peroxisome proliferator-activated receptor gamma (PPAR&#x003b3;) improves insulin sensitivity and lowers circulating levels of glucose, triglycerides and free fatty acids without stimulating insulin secretion in rodent models of T2D [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. PPAR&#x003b3; agonists also alleviate peripheral insulin resistance in humans, and have been effectively used in treatment of T2D patients [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Fatty acid binding protein(FABP3), adipocyte lipid binding protein(aP2) and lipoprotein lipase (LPL)are response genes of PPAR&#x003b3; and are indicators for in vivo PPAR&#x003b3; activation in adipose tissue [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Adiponectin, an adipose-specific plasma protein, possesses insulin sensitizing and anti-atherogenic properties [<xref ref-type="bibr" rid="B10">10</xref>]. It has been well documented that plasma adiponectin is lower in obese subjects than in lean subjects, lower in diabetic patients than in non-diabetic patients [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>], and is negatively correlated with body weight, visceral fat mass, and resting insulin level [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Hotta et al also reported that adiponectin decreased in parallel with the progression of T2D in rhesus monkeys, and there is a strong correlation between plasma adiponectin and systemic insulin sensitivity [<xref ref-type="bibr" rid="B14">14</xref>]. Studies by Maeda et al showed that adiponectin knockout mice developed hyperglycemia and hyperinsulinemia while on HF diet, which was reversed by adenoviral-mediated adiponectin expression [<xref ref-type="bibr" rid="B15">15</xref>]. Exogenous adiponectin also lowered hepatic glucose production during a pancreatic euglycemic clamp [<xref ref-type="bibr" rid="B16">16</xref>], and increased post-absorptive insulin-mediated suppression of hepatic glucose output [<xref ref-type="bibr" rid="B10">10</xref>]. The PPAR&#x003b3; agonist, class of insulin sensitizer, has the marked effect of up-regulating serum adiponectin. Combs et al reported that the PPAR&#x003b3; agonist rosiglitazone increased plasma adiponectin in <italic>db/db </italic>mice [<xref ref-type="bibr" rid="B17">17</xref>]. Yang et al reported rosiglitazone increased plasma levels of adiponectin in type 2 diabetic patients [<xref ref-type="bibr" rid="B18">18</xref>]. Tschritter et al analyzed the associations between plasma adiponectin and insulin sensitivity and serum lipid parameters in nondiabetic individuals, and concluded that plasma adiponectin predicts insulin sensitivity of both glucose and lipid metabolism [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>While PPAR&#x003b3; agonists increase plasma adiponectin and adiponectin levels predict insulin sensitivity, there is not a clear demonstration of the relationships among PPAR&#x003b3; agonist-increased adiponectin and PPAR&#x003b3; agonist-mediated efficacy on insulin sensitivity/in vivo PPAR&#x003b3; activation. Therefore, the current studies were designed to define these relationships and assess serum adiponectin as a biomarker for in vivo PPAR&#x003b3; activation and PPAR&#x003b3; agonist-induced efficacy on insulin sensitization and lipid lowering.</p></sec><sec><title>Results</title><sec><title>High fat/sucrose (HF) diet induced changes in SD rats</title><p>Rats on the HF diet for 4 weeks showed marked insulin resistance and dyslipidemia, indicated by significant increases in postprandial serum levels of triglycerides, free fatty acids, insulin, and area under curve (AUC) for serum insulin during OGTT. But the HF diet did not cause changes in postprandial serum glucose or OGTT glucose AUC compared with rats on normal diet, consistent with an insulin resistant, pre-diabetic phenotype. Serum adiponectin level in rats on HF diet was slightly higher than that in normal diet rats at week 2, but back to the same level at week 4 (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>HF diet induced changes in SD rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>Normal diet</bold></td><td align="left"><bold>HF diet</bold></td></tr></thead><tbody><tr><td align="left" colspan="3">Triglyceride (mg/dL)</td></tr><tr><td align="left">Prior to start</td><td align="left">95.0 &#x000b1; 8.7</td><td align="left">115.6 &#x000b1; 13.7</td></tr><tr><td align="left">2 weeks diet</td><td align="left">100.4 &#x000b1; 7.6</td><td align="left">446.2 &#x000b1; 38.7**++</td></tr><tr><td align="left">4 weeks diet</td><td align="left">121.7 &#x000b1; 9.1</td><td align="left">388.1 &#x000b1; 44.5**++</td></tr><tr><td align="left" colspan="3">Free fatty acid (mEq/L)</td></tr><tr><td align="left">Prior to start</td><td align="left">0.36 &#x000b1; 0.05</td><td align="left">0.41 &#x000b1; 0.04</td></tr><tr><td align="left">2 weeks diet</td><td align="left">0.38 &#x000b1; 0.05</td><td align="left">0.56 &#x000b1; 0.04**++</td></tr><tr><td align="left">4 weeks diet</td><td align="left">0.24 &#x000b1; 0.02</td><td align="left">0.67 &#x000b1; 0.06**++</td></tr><tr><td align="left" colspan="3">Glucose (mg/dL)</td></tr><tr><td align="left">Prior to start</td><td align="left">166.8 &#x000b1; 5.3</td><td align="left">162.8 &#x000b1; 4.3</td></tr><tr><td align="left">2 weeks diet</td><td align="left">170.0 &#x000b1; 11.3</td><td align="left">174.1 &#x000b1; 2.5</td></tr><tr><td align="left">4 weeks diet</td><td align="left">176.6 &#x000b1; 2.8</td><td align="left">167.0 &#x000b1; 4.0</td></tr><tr><td align="left" colspan="3">Post-prandial insulin (ng/ml)</td></tr><tr><td align="left">Prior to start</td><td align="left">0.71 &#x000b1; 0.11</td><td align="left">1.06 &#x000b1; 0.15</td></tr><tr><td align="left">2 weeks diet</td><td align="left">1.26 &#x000b1; 0.29</td><td align="left">2.72 &#x000b1; 0.47**++</td></tr><tr><td align="left">4 weeks diet</td><td align="left">1.23 &#x000b1; 0.22</td><td align="left">2.39 &#x000b1; 0.35**++</td></tr><tr><td align="left" colspan="3">Insulin AUC during OGTT</td></tr><tr><td align="left">4 weeks diet</td><td align="left">241.6 &#x000b1; 19.5</td><td align="left">528.6 &#x000b1; 84.9**</td></tr><tr><td align="left" colspan="3">Glucose AUC during OGTT</td></tr><tr><td align="left">4 weeks diet</td><td align="left">7360 &#x000b1; 416</td><td align="left">7533 &#x000b1; 496</td></tr><tr><td align="left" colspan="3">Serum adiponectin (&#x003bc;g/ml)</td></tr><tr><td align="left">Prior to start</td><td align="left">3.59 &#x000b1; 0.25</td><td align="left">3.53 &#x000b1; 0.25</td></tr><tr><td align="left">2 weeks diet</td><td align="left">3.64 &#x000b1; 0.32</td><td align="left">4.96 &#x000b1; 0.41*</td></tr><tr><td align="left">4 weeks diet</td><td align="left">3.75 &#x000b1; 0.40</td><td align="left">4.35 &#x000b1; 0.40</td></tr></tbody></table><table-wrap-foot><p>*p &#x0003c; 0.05 vs Before diet, **p &#x0003c; 0.01 vs Before diet, ++p &#x0003c; 0.01 vs Normal diet.</p></table-wrap-foot></table-wrap></sec><sec><title>PPAR&#x003b3; agonist on adiponectin in SD rats</title><p>As showed in Fig. <xref ref-type="fig" rid="F1">1</xref>, treatment of SD rats on HF diet with GI262570 for 2 weeks dose-dependently increased serum adiponectin, and upregulated adipose FABP3 mRNA without effect on housekeeper genes 18S, &#x003b2;-actin, and cyclophilin. There was a positive correlation between adipose FABP3 mRNA and serum adiponectin (Pearson Correlation Coefficients 0.7350, p &#x0003c; 0.01). A marked increase in serum adiponectin was also observed in GW347845-treated HF fed SD rats (30.93 &#x000b1; 0.45 vs 4.86 &#x000b1; 0.30 &#x003bc;g/ml in vehicle. p &#x0003c; 0.01).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Efeects of PPAR&#x003b3; agonist GI262570 on serum adiponectin level (a), adipose FABP3 mRNA level (b), and the correlation between serum adiponectin and adipose FABP3 mRNA. SD rats were on HF diet for 4 weeks. GI262570 was oral dosed for the later 2 weeks. Mean &#x000b1; SEM. N = 5&#x02013;8 in each group. *p &#x0003c; 0.05 vs vehicle. **p &#x0003c; 0.01 vs vehicle.</p></caption><graphic xlink:href="1471-2210-4-23-1"></graphic></fig></sec><sec><title>PPAR&#x003b3; agonist-increased serum adiponectin and PPAR&#x003b3; agonist-mediated efficacy on insulin sensitivity and lipid lowering</title><p>Treatment of rats on HF diet with GI262570 for 2 weeks significantly decreased the diet-induced elevations in postprandial serum triglycerides, free fatty acids, insulin, and insulin AUC in a dose-dependent manner (Fig. <xref ref-type="fig" rid="F2">2</xref>). Treatment with GW347845 showed a qualitatively similar effect to that of GI262570 treatment (Table <xref ref-type="table" rid="T2">2</xref>). There were negative correlations for adiponectin versus triglycerides, free fatty acids, insulin, and insulin AUC (For GI262570, r = -0.7486, -0.4581, -0.4379, and -0.3258; p &#x0003c; 0.005, 0.005, 0.01 and 0.05 respectively, Fig. <xref ref-type="fig" rid="F3">3</xref>; For GW347845, r = -0.6370, -0.6877, -0.5512, and -0.3812, p &#x0003c; 0.01, 0.01, 0.01 and 0.05 respectively, Table <xref ref-type="table" rid="T2">2</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Effects of PPAR&#x003b3; agonist GI262570 on serum insulin, triglycerides, free fatty acids, and insulin AUC during OGTT. SD rats were on HF diet for 4 weeks. GI262570 was oral dosed for the later 2 weeks. Mean &#x000b1; SEM. N = 7&#x02013;9 in each group.</p></caption><graphic xlink:href="1471-2210-4-23-2"></graphic></fig><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Effect of GW347845 (3 mg/kg, B.I.D.) in rats on HF diet.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">Triglycerides (mg/dL)</td><td align="center">FFA (mEq/L)</td><td align="center">Serum Insulin (ng/ml)</td><td align="center">Insulin AUC (min &#x000d7; ng/ml)</td></tr></thead><tbody><tr><td align="left">Normal diet</td><td align="center">98.6 &#x000b1; 8.6</td><td align="center">0.26 &#x000b1; 0.03</td><td align="center">1.34 &#x000b1; 0.19</td><td align="center">241.0 &#x000b1; 22.8</td></tr><tr><td align="left">Diet-Vehicle</td><td align="center">455.6 &#x000b1; 94.2**</td><td align="center">0.65 &#x000b1; 0.07**</td><td align="center">1.88 &#x000b1; 0.16*</td><td align="center">356.9 &#x000b1; 25.3**</td></tr><tr><td align="left">Diet-GW347845</td><td align="center">139.4 &#x000b1; 14.8++</td><td align="center">0.37 &#x000b1; 0.03++</td><td align="center">1.16 &#x000b1; 0.08++</td><td align="center">267.9 &#x000b1; 34.2</td></tr><tr><td align="left">Corr. Coeff.</td><td align="center">-0.637</td><td align="center">-0.6877</td><td align="center">-0.5512</td><td align="center">-0.3812</td></tr><tr><td align="left">Vs adiponectin</td><td align="center">p &#x0003c; 0.01</td><td align="center">p &#x0003c; 0.01</td><td align="center">p &#x0003c; 0.01</td><td align="center">p &#x0003c; 0.05</td></tr></tbody></table><table-wrap-foot><p>Corr. Coeff.: Pearson Correlation Coefficient. *p &#x0003c; 0.05 vs Normal diet. **p &#x0003c; 0.01 vs normal diet. <sup>++</sup>p &#x0003c; 0.01 vs diet-vehicle. N = 7&#x02013;8 in each group.</p></table-wrap-foot></table-wrap><fig position="float" id="F3"><label>Figure 3</label><caption><p>Correlation between PPAR&#x003b3; agonist GI262570 (0.2&#x02013;100 mg/kg)-elevated serum adiponectin and GI262570-decreased serum insulin, triglycerides, free fatty acids, and insulin AUC during OGTT in HF fed SD rats.</p></caption><graphic xlink:href="1471-2210-4-23-3"></graphic></fig></sec><sec><title>PPAR&#x003b3; agonists in Zucker rats</title><p>Compared with Zucker lean rats, ZDF rats had higher serum insulin, glucose, TG, FFA, but similar serum adiponectin levels. Treatment of ZDF rats with PPAR&#x003b3; agonist pioglitazone or GW347845 for 2 weeks resulted in significantly lower serum glucose, triglycerides, free fatty acids, and modestly lower serum insulin, compared to vehicle treatment. Both pioglitazone and GW347845 markedly increased serum adiponectin in ZDF rats (Table <xref ref-type="table" rid="T3">3</xref>). There were also negative correlations for serum adiponectin versus glucose, TG, FFA (for pioglitazone, r = -0.7005, -0.8603, and -0.9288 respectively; for GW347845, r = -0.9721, -0.8483, and -0.9453 respectively, all p &#x0003c; 0.01).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Effect of pioglitazone and GW347845 in ZDF rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Insulin (ng/ml)</td><td align="center">Glucose (mg/dL)</td><td align="center">Triglycerides (mg/dL)</td><td align="center">FFA (mEq/L)</td><td align="center">Adiponectin (&#x003bc;g/ml)</td></tr></thead><tbody><tr><td align="left" colspan="6">ZDF lean rats</td></tr><tr><td align="left">Vehicle</td><td align="center">0.3 &#x000b1; 0.1</td><td align="center">158 &#x000b1; 4</td><td align="center">82 &#x000b1; 7</td><td align="center">0.31 &#x000b1; 0.02</td><td align="center">10.2 &#x000b1; 0.5</td></tr><tr><td align="left" colspan="6">ZDF rats</td></tr><tr><td align="left">Vehicle</td><td align="center">2.9 &#x000b1; 0.5**</td><td align="center">525 &#x000b1; 25**</td><td align="center">912 &#x000b1; 97**</td><td align="center">0.62 &#x000b1; 0.03**</td><td align="center">10.0 &#x000b1; 1.1</td></tr><tr><td align="left" colspan="6">Pioglitazone (mg/kg, B.I.D)</td></tr><tr><td align="center">3</td><td align="center">2.5 &#x000b1; 0.6<sup>+</sup></td><td align="center">214 &#x000b1; 64<sup>+</sup></td><td align="center">251 &#x000b1; 81<sup>++</sup></td><td align="center">0.26 &#x000b1; 0.09<sup>++</sup></td><td align="center">44.0 &#x000b1; 7.7<sup>++</sup></td></tr><tr><td align="center">10</td><td align="center">2.8 &#x000b1; 0.5</td><td align="center">154 &#x000b1; 17<sup>++</sup></td><td align="center">129 &#x000b1; 19<sup>++</sup></td><td align="center">0.16 &#x000b1; 0.01<sup>++</sup></td><td align="center">60.0 &#x000b1; 1.5<sup>++</sup></td></tr><tr><td align="center">30</td><td align="center">2.3 &#x000b1; 0.4<sup>+</sup></td><td align="center">154 &#x000b1; 9<sup>++</sup></td><td align="center">129 &#x000b1; 16<sup>++</sup></td><td align="center">0.14 &#x000b1; 0.01<sup>++</sup></td><td align="center">63.0 &#x000b1; 0.8<sup>++</sup></td></tr><tr><td align="left" colspan="6">GW347845 (mg/kg, B.I.D)</td></tr><tr><td align="center">3</td><td align="center">1.7 &#x000b1; 0.2<sup>++</sup></td><td align="center">147 &#x000b1; 6<sup>++</sup></td><td align="center">95 &#x000b1; 10<sup>++</sup></td><td align="center">0.12 &#x000b1; 0.01<sup>++</sup></td><td align="center">66.1 &#x000b1; 0.6<sup>++</sup></td></tr></tbody></table><table-wrap-foot><p>**p &#x0003c; 0.01 vs ZDF lean rats. <sup>+ </sup>p &#x0003c; 0.05 vs Vehicle-treated ZDF rats. <sup>++</sup>p &#x0003c; 0.01 vs Vehicle-treated ZDF rats. N = 6&#x02013;12 in each group.</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>Adiponectin possesses insulin sensitizing and anti-atherogenic properties [<xref ref-type="bibr" rid="B10">10</xref>]. In most clinical reports, primate studies, and genetic models, serum adiponectin level had been reported to be negatively correlated with body weight, visceral fat mass, and resting insulin level [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. The present study showed that rats fed a HF diet had significantly higher serum insulin and lipids with in 2 weeks, which indicates insulin resistance. However, serum adiponectin level was not decreased by the diet up to 4 weeks. We have subsequently kept rats on the HF diet for up to 20 weeks, and observed a slight increase (instead of decrease) in serum adiponectin level (data not shown). Our data may suggest that the HF diet-induced insulin resistance happened much early than diet-induced change in serum adiponectin. Our data is consistent with studies by Naderali EK et al [<xref ref-type="bibr" rid="B19">19</xref>]. In their report, 16 weeks of high fat/glucose diet resulted in significantly higher body weight, fat pad masses, plasma leptin, and higher plasma level of adiponectin, besides higher levels of plasma TG and FFA.</p><p>PPAR&#x003b3; is a member of the PPAR family of the nuclear receptor superfamily [<xref ref-type="bibr" rid="B6">6</xref>]. PPAR&#x003b3; agonists increase insulin sensitivity and circulating adiponectin [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. The response genes of PPAR&#x003b3; for in vivo PPAR&#x003b3; activation include LPL, AP2 and FABP3 [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. The current study demonstrated that as in other species the PPAR&#x003b3; agonist GI262570 upregulated serum adiponectin level and adipose FABP3 mRNA level in SD rats in a dose-dependent manner. Interestingly, there is a positive correlation between PPAR&#x003b3; full agonist-upregulated serum adiponectin level and adipose FABP3 mRNA level, demonstrating the serum adiponectin level could be a biomarker for in vivo PPAR&#x003b3; activation.</p><p>We did perform parallel experiments to check mRNA levels of PPAR&#x003b3; response genes FABP3, aP2 and LPL in epididymal fat. We found that basal level of FABP3 mRNA was very low compared to aP2 and LPL (FABP3:LPL:aP2 = ~1:250:2500), and that PPAR&#x003b3; agonist GI262570 dose-dependently increased FABP3 mRNA. AP2 was abundant in epididymal fat tissues, and was only slightly increased by GI262570 in a non-dose-dependent manner (data not shown). LPL was decreased in high fat diet fed rats, which was reversed by GI262570 but not dose-dependently (data not shown). With in vivo chronic exposure, the effect of PPAR&#x003b3; agonists on gene expression is difficult to separate from the effects on differentiation. In general we find aP2 a better marker of adipocyte differentiation than PPAR&#x003b3; activation. Since PPAR&#x003b3; agonist-mediated action in vivo may vary with organs/tissues (such as liver vs fat; subcutaneous fat vs omental or epididymal fat) [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>] and duration of treatment, all PPAR&#x003b3; response genes may not be changed in the same manner in one tissue following chronic treatment. Therefore the authors consider that the dose-dependently GI262570 upregulated FABP3 mRNA in epididymal fat caught in the present study is of value for quantitative in vivo PPAR&#x003b3; activation. Thus the correlation data using FABP3 mRNA is of value.</p><p>Adiponectin has been demonstrated to have an insulin sensitizing effect [<xref ref-type="bibr" rid="B10">10</xref>]. Circulating adiponectin levels were positively correlated with insulin sensitivity, measured both by an euglycemic-hyperinsulinemic clamp and estimated by an oral glucose tolerant test, were negatively correlated with fasting lipids [<xref ref-type="bibr" rid="B22">22</xref>]. The PPAR&#x003b3; agonist rosiglitazone increased plasma level of adiponectin, decreased fasting plasma glucose and HBA<sub>1C</sub>, and ameliorated insulin resistance in type 2 diabetic patients [<xref ref-type="bibr" rid="B18">18</xref>]. However, the relationship between PPAR&#x003b3; agonist-increased circulating adiponectin and PPAR&#x003b3; agonist-induced efficacy on insulin resistance has not been studied. The current study showed that PPAR&#x003b3; agonists increased serum levels of adiponectin, ameliorated insulin resistance and lipid profile in both diet-induced insulin resistant rats and ZDF rats. There is a correlation between PPAR&#x003b3; agonist-increased serum adiponectin level and PPAR&#x003b3; agonist-induced efficacy in insulin sensitivity/lipid lowering. These data provide a link between PPAR&#x003b3; agonist-elevated circulating adiponectin level and PPAR&#x003b3; agonist-mediated efficacy in insulin sensitivity and lipid lowering, and indicate that serum adiponectin level could be a biomarker for in vivo PPAR&#x003b3; efficacy.</p><p>Other adipokines, such as leptin, are important in obesity and insulin resistance. Unlike adiponectin, leptin is positively correlated with fat amount, mass and percentage [<xref ref-type="bibr" rid="B23">23</xref>]. It has been reported that PPAR&#x003b3; agonists inhibit the expression and function of leptin [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Our unpublished study showed that high fat diet resulted in insulin resistance and higher serum leptin level in rats. Treatment of these insulin resistant rats with PPAR&#x003b3; agonist GW7845 improved insulin sensitivity, but did not affect serum leptin level. Therefore leptin is not considered to be a marker for PPAR&#x003b3; efficacy. There are indices for in vivo PPAR&#x003b3; activation (i.g., adipose FABP3 mRNA), or for in vivo PPAR&#x003b3; efficacy on insulin sensitization (i.g., serum insulin and glucose). These indices can not be used to represent both in vivo PPAR&#x003b3; activation and in vivo PPAR&#x003b3; efficacy on insulin sensitization. It is well known that circulating adiponectin increases insulin sensitivity [<xref ref-type="bibr" rid="B10">10</xref>], is decreased in T2D patients [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>], and is negatively correlated with insulin resistance [<xref ref-type="bibr" rid="B22">22</xref>]; PPAR&#x003b3; agonists increase insulin sensitivity as well as circulating adiponectin [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. The correlations, serum adiponectin vs adipose FABP3 mRNA and serum adiponectin vs insulin/lipids, in our study demonstrated that serum adiponectin is a good biomarker for both in vivo PPAR&#x003b3; activation and in vivo PPAR&#x003b3; efficacy on insulin sensitization.</p></sec><sec><title>Conclusions</title><p>These studies demonstrated that in both diet-induced and genetic rat models of insulin resistant (metabolic) syndrome the full PPAR&#x003b3; agonists GI262570, GW347845, and pioglitazone significantly elevated serum adiponectin levels, increased adipose transcription of the PPAR&#x003b3; response gene FABP3, and were efficacious as expected. This is the first demonstration of correlation among PPAR&#x003b3; agonist-increased serum adiponectin, PPAR&#x003b3; agonist response gene mRNA, and PPAR&#x003b3; agonist-mediated efficacy in insulin sensitivity and lipid lowering. These data indicate that serum adiponectin can serve as a biomarker for both in vivo PPAR&#x003b3; activation and PPAR&#x003b3; agonist-induced efficacy in rats.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Experimental animal and protocols</title><p>All procedures performed were in compliance with the Animal Welfare Act and U.S. Department of Agriculture regulations, and were approved by the GlaxoSmithKline Animal Care and Use Committee. Male caesarian derived Sprague Dawley rats (SD, 225&#x02013;250 g) (Charles River, Indianapolis, IN) were fed rodent chow Purina 5001 (Harlan Teklad, Indianapolis, IN). Male Zucker diabetic fatty (ZDF) and male Zucker lean rats (8 weeks old) (Genetic Models, Indianapolis, IN) were fed Formulab Diet 5008 (PMI Feeds, Richmond, IN). After an adaptation period of 1 week, SD rats were fed a HF diet (TD88137, Containing 34.146% sucrose. 42% of calories from fat. Harlan Teklad, Indianapolis, IN) for 4 weeks. SD Rats fed chow Purina 5001 served as normal diet control. SD rats on HF diet were treated with vehicle (0.5% hydroxypropyl methylcellulose and 0.1% Tween 80), PPAR&#x003b3; agonist GI262570 [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B28">28</xref>] (0.2, 2, 20, or 100 mg/kg, QD), or PPAR&#x003b3; agonist GW347845 (3 mg/kg, BID) for the last 2 weeks. ZDF rats were gavaged twice daily for 14 days with vehicle, PPAR&#x003b3; agonist pioglitazone [<xref ref-type="bibr" rid="B4">4</xref>] (3, 10, or 30 mg/kg), or PPAR&#x003b3; agonist GW347845 (3 mg/kg) [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Zucker lean rats were gavaged twice daily for 14 days with vehicle. One day prior to the end of dosing (after 13 days of dosing), serum was obtained from tail vein of SD rats for determining postprandial levels of glucose, insulin, triglycerides, free fatty acids, and adiponectin. The SD rats were then implanted with a jugular cannula. Oral glucose tolerant tests (OGTT) were performed in these SD rats after 14 days of dosing. At the end of the study, SD rats were euthanized with CO<sub>2</sub>. White adipose tissue (WAT, epididymal fat pad) were saved for determining mRNA levels of PPAR&#x003b3; response gene FABP3. In Zucker rats, serum was collected after 2 weeks of dosing for determining postprandial levels of glucose, insulin, triglycerides, free fatty acids, and adiponectin. Zucker rats were then euthanized with CO<sub>2</sub>.</p></sec><sec><title>Determination of postprandial serum chemicals</title><p>Serum glucose, triglycerides, and free fatty acids were measured using Ilab600 Clinical Chemistry System (Instrumentation Laboratory).</p></sec><sec><title>Determination of serum adiponectin</title><p>Serum adiponectin of SD rats was determined by using adiponectin RIA kit (Linco Research, MO), according to the manufacture's instruction. Serum adiponectin of ZDF rats was determined by using adiponectin ELISA kit (B-Bridge International, CA), according to the manufacture's instruction.</p></sec><sec><title>Jugular vein cannulation</title><p>Under anesthesia with isoflurane, surgical site was prepared using standard aseptic technique (with Hiboclens<sup>&#x000ae; </sup>Chlorhexidine Gluconate, Zeneca Pharmaceuticals, Delaware). A longitudinal incision was made over the right external jugular vein. 5&#x02013;10 mm of the vein was exposed by blunt dissection. Jugular cannula (Access&#x02122; Technologies, IL) was inserted into the vein for about 1 inch. The cannula was secured using sterile sutures. The cannula was routed subcutaneously, exteriorized between the scapulae. The cannula was then filled with dextrose-heparin solution (50:50), and heat sealed.</p></sec><sec><title>OGTT</title><p>Rats implanted with jugular cannula were fasted overnight. The following morning, dextrose (0.5 g/ml in water, 2 g/kg body weight) was administered by oral gavage. Blood samples (0.3 ml/time) were obtained from the jugular cannula before gavage, 10, 20, 30, 45, 60, 90 and 120 min after gavage. Blood glucose was immediately measured by using Elite<sup>&#x000ae; </sup>XL Glucometer (Bayer, Tarrytown, NY). Serum was collected for insulin measurement. Area under curves (AUCs) for glucose and insulin during OGTT were calculated by using WinNonlin&#x02122; Noncompartmental Model 200.</p></sec><sec><title>Determination of insulin level</title><p>Serum insulin of SD rats level was determined using Rat Insulin ELISA kit (Crystal Chem Inc, IL), according to the manufacture's instruction. Serum insulin level of ZDF rats was determined using Igen's M-SERIES M-8 Analyzer (Igen International, Inc., Gaithersburg, MD).</p></sec><sec><title>Determination of FABP3 mRNA level in white adipose tissue by real time PCR</title><p>Total RNA in epididymal fat pad was isolated by the TRIZOL<sup>&#x000ae; </sup>method [<xref ref-type="bibr" rid="B31">31</xref>]. All RNA samples were DNased using the DNA-<italic>free</italic>&#x02122; kit (Ambion &#x02013; according to protocol). The samples were then quantitated by RiboGreen&#x02122; (Molecular Probes &#x02013; according to protocol). GAPDH gene expression was analyzed in the absence of reverse transcriptase to ensure the samples were free of genomic DNA. The samples were then converted to cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems &#x02013; according to protocol). Samples were diluted to a final concentration of 5 ng/ul of cDNA. PCR results were generated using the 5' nuclease assay (TaqMan) [<xref ref-type="bibr" rid="B32">32</xref>] and the ABI 7900 Sequence Detection System (Applied Biosystems, Foster City, CA). Primers and probe for FABP3 are: Forward-GTCGTGACACTGGACGGAGG; Reverse-TTCCCATCACTTAGTTCCCGTG; Probe-CAGAAGTGGGACGGGCAGGAGACTACG. The primers and probe for Cyclophilin are: Forward-TATCTGCACTGCCAAGACTGA; Reverse-CCACAATGCTCATGCCTTCTTTCA; Probe-CCAAAGACCACATGCTTGCCATCCA. A master mixture was utilized which included 900 nM each of the forward and reverse primers, 100 nM probe, and 1 &#x000d7; PCR master mix (Applied Biosystems). The PCR reaction consisted of 12.5 ng of cDNA in a 12.5 ul total reaction volume. The PCR cycling conditions were 95&#x000b0;C for 10 minutes, and 40 cycles of 95&#x000b0;C for 15 seconds and 60&#x000b0;C for 1 minute.</p></sec><sec><title>Statistical analysis</title><p>There was a minimum of 5 rats for each data point. Data are presented as mean &#x000b1; SEM. Correlation between two parameters and the significant level of correlation were analyzed by Pearson correlation analysis. Differences between vehicle and treated groups were analyzed by two-way ANOVA. P less than 0.05 was taken to be significant.</p></sec></sec><sec><title>List of abbreviations</title><p>QD: Once a day</p><p>BID: Twice a day</p><p>PCR: Polymerase Chain Reaction</p><p>GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase</p><p>ANOVA: Analysis of Variance</p></sec><sec><title>Authors' contributions</title><p>BY is the principal investigator. LC, LGC, JM, and DW participated in the in vivo experiments. KC and JS performed the real time PCR. KB, SS and GP participated in study design and manuscript preparation.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Qiming Liao for his assistance in statistical analysis, and Jane Binz for her assistance in measuring serum glucose, triglycerides, and free fatty acids.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Henke</surname><given-names>BH</given-names></name><name><surname>Blanchard</surname><given-names>SG</given-names></name><name><surname>Cobb</surname><given-names>JE</given-names></name><name><surname>Mook</surname><given-names>R</given-names></name><name><surname>Kaldor</surname><given-names>I</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name><name><surname>Lehmann</surname><given-names>JM</given-names></name><name><surname>Lenhard</surname><given-names>JM</given-names></name><name><surname>Harrington</surname><given-names>WW</given-names></name><name><surname>Novak</surname><given-names>PJ</given-names></name><name><surname>Faison</surname><given-names>W</given-names></name><name><surname>Binz</surname><given-names>JG</given-names></name><name><surname>Hashim</surname><given-names>MA</given-names></name><name><surname>Oliver</surname><given-names>WO</given-names></name><name><surname>Brown</surname><given-names>HR</given-names></name><name><surname>Parks</surname><given-names>DJ</given-names></name><name><surname>Plunket</surname><given-names>KD</given-names></name><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Menius</surname><given-names>JA</given-names></name><name><surname>Adkison</surname><given-names>K</given-names></name><name><surname>Noble</surname><given-names>SA</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name></person-group><article-title>A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat</article-title><source>Diabetes</source><year>1999</year><volume>48</volume><fpage>1415</fpage><lpage>1424</lpage><pub-id pub-id-type="pmid">10389847</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Brown</surname><given-names>PJ</given-names></name><name><surname>Sternbach</surname><given-names>DD</given-names></name><name><surname>Henke</surname><given-names>BR</given-names></name></person-group><article-title>The PPARs: From orphan receptors to drug discovery</article-title><source>J Medicinal Chem</source><year>2000</year><volume>43</volume><fpage>527</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1021/jm990554g</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virtanen</surname><given-names>KA</given-names></name><name><surname>Hallsten</surname><given-names>K</given-names></name><name><surname>Parkkola</surname><given-names>R</given-names></name><name><surname>Janatuinen</surname><given-names>T</given-names></name><name><surname>Lonnqvist</surname><given-names>F</given-names></name><name><surname>Viljanen</surname><given-names>T</given-names></name><name><surname>Ronnemaa</surname><given-names>T</given-names></name><name><surname>Knuuti</surname><given-names>J</given-names></name><name><surname>Huupponen</surname><given-names>R</given-names></name><name><surname>Lonnroth</surname><given-names>P</given-names></name><name><surname>Nuutila</surname><given-names>P</given-names></name></person-group><article-title>Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetes subjects</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>283</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">12540598</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirose</surname><given-names>H</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Taniyama</surname><given-names>M</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Matsubara</surname><given-names>K</given-names></name><name><surname>Okazaki</surname><given-names>Y</given-names></name><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Oguma</surname><given-names>Y</given-names></name><name><surname>Takei</surname><given-names>I</given-names></name><name><surname>Saruta</surname><given-names>T</given-names></name></person-group><article-title>Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes</article-title><source>Metabolism</source><year>2002</year><volume>51</volume><fpage>314</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">11887166</pub-id><pub-id pub-id-type="doi">10.1053/meta.2002.30506</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pavo</surname><given-names>I</given-names></name><name><surname>Jermendy</surname><given-names>G</given-names></name><name><surname>Varkonyi</surname><given-names>TT</given-names></name><name><surname>Kerenyi</surname><given-names>Z</given-names></name><name><surname>Gyimesi</surname><given-names>A</given-names></name><name><surname>Shoustov</surname><given-names>S</given-names></name><name><surname>Shestakova</surname><given-names>M</given-names></name><name><surname>Herz</surname><given-names>M</given-names></name><name><surname>Johns</surname><given-names>D</given-names></name><name><surname>Schluchter</surname><given-names>BJ</given-names></name><name><surname>Festa</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>MH</given-names></name></person-group><article-title>Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes</article-title><source>J Clin Endocrino Metabolism</source><year>2003</year><volume>88</volume><fpage>1637</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-021786</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desvergne</surname><given-names>B</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors: Nuclear control of metabolism</article-title><source>Endocrine Rev</source><year>1999</year><volume>20</volume><fpage>649</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">10529898</pub-id><pub-id pub-id-type="doi">10.1210/er.20.5.649</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Clifton</surname><given-names>LG</given-names></name><name><surname>McNulty</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Baer</surname><given-names>PG</given-names></name></person-group><article-title>Effects of a PPARgamma agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats</article-title><source>J Cardiovasc Pharmacol</source><year>2003</year><volume>42</volume><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">12960690</pub-id><pub-id pub-id-type="doi">10.1097/00005344-200309000-00016</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>SL</given-names></name><name><surname>Cawthorne</surname><given-names>MA</given-names></name><name><surname>Clapham</surname><given-names>JC</given-names></name><name><surname>Dunmore</surname><given-names>SJ</given-names></name><name><surname>Holmes</surname><given-names>SD</given-names></name><name><surname>Moore</surname><given-names>GBT</given-names></name><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>Tadayyon</surname><given-names>M</given-names></name></person-group><article-title>The thiozolidinedione insulin sensitiser, BRL 49653, increases the expression of PPARgamma and aP2 in adipose tissue of high-fat-fed rats</article-title><source>Biochemical &#x00026; Biophysical Research Communications</source><year>1996</year><volume>299</volume><fpage>752</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">8954968</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1996.1876</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Way</surname><given-names>JM</given-names></name><name><surname>Harrington</surname><given-names>WW</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Gottschalk</surname><given-names>WK</given-names></name><name><surname>Sundseth</surname><given-names>SS</given-names></name><name><surname>Mansfield</surname><given-names>TA</given-names></name><name><surname>Ramachandran</surname><given-names>RK</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name></person-group><article-title>Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues</article-title><source>Endocrinology</source><year>2001</year><volume>142</volume><fpage>1269</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">11181544</pub-id><pub-id pub-id-type="doi">10.1210/en.142.3.1269</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>AH</given-names></name><name><surname>Combs</surname><given-names>TP</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name></person-group><article-title>ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism</article-title><source>TRENDS Endocrinol Metabolism</source><year>2002</year><volume>13</volume><fpage>84</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/S1043-2760(01)00524-0</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>[Molecular mechanism in the development of the complications associated with obesity &#x02013; the physiological and pathological role of adipocytokines]</article-title><source>Nippon Rinsho</source><year>2001</year><volume>59</volume><fpage>481</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">11268596</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Iwahashi</surname><given-names>H</given-names></name><name><surname>Kuriyama</surname><given-names>H</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Muraguchi</surname><given-names>M</given-names></name><name><surname>Ohmoto</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Hanafusa</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2000</year><volume>20</volume><fpage>1595</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">10845877</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Miyagawa</surname><given-names>J</given-names></name><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Miyaoka</surname><given-names>K</given-names></name><name><surname>Kuriyama</surname><given-names>H</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Okubo</surname><given-names>K</given-names></name><name><surname>Matsubara</surname><given-names>K</given-names></name><name><surname>Muraguchi</surname><given-names>M</given-names></name><name><surname>Ohmoto</surname><given-names>Y</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity</article-title><source>Biochemical &#x00026; Biophysical Research Communications</source><year>1999</year><volume>257</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">10092513</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1999.0255</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Bodkin</surname><given-names>NL</given-names></name><name><surname>Ortmeyer</surname><given-names>HK</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Hansen</surname><given-names>BC</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys</article-title><source>Diabetes</source><year>2001</year><volume>50</volume><fpage>1126</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">11334417</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>N</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name><name><surname>Kishida</surname><given-names>K</given-names></name><name><surname>Nishizawa</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Nagaretani</surname><given-names>H</given-names></name><name><surname>Furuyama</surname><given-names>N</given-names></name><name><surname>Kondo</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Komuro</surname><given-names>R</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Tochino</surname><given-names>Y</given-names></name><name><surname>Okutomi</surname><given-names>K</given-names></name><name><surname>Horie</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Aoyama</surname><given-names>T</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Diet-induced insulin resistance in mice lacking adiponectin/ACRP30</article-title><source>Nature Medicine</source><year>2002</year><volume>8</volume><fpage>731</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">12068289</pub-id><pub-id pub-id-type="doi">10.1038/nm724</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combs</surname><given-names>TP</given-names></name><name><surname>Berg</surname><given-names>AH</given-names></name><name><surname>Obici</surname><given-names>S</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name><name><surname>Rossetti</surname><given-names>L</given-names></name></person-group><article-title>Endogenous glucose production is inhibited by the adipose-derived protein Acrp30</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><fpage>1875</fpage><lpage>1881</lpage><pub-id pub-id-type="pmid">11748271</pub-id><pub-id pub-id-type="doi">10.1172/JCI200114120</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combs</surname><given-names>TP</given-names></name><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Berger</surname><given-names>J</given-names></name><name><surname>Doebber</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>WJ</given-names></name><name><surname>Zhang</surname><given-names>BB</given-names></name><name><surname>Tanen</surname><given-names>M</given-names></name><name><surname>Berg</surname><given-names>AH</given-names></name><name><surname>O'Rahilly</surname><given-names>S</given-names></name><name><surname>Savage</surname><given-names>DB</given-names></name><name><surname>Chatterjee</surname><given-names>K</given-names></name><name><surname>Weiss</surname><given-names>S</given-names></name><name><surname>Larson</surname><given-names>PJ</given-names></name><name><surname>Gottesdiener</surname><given-names>KM</given-names></name><name><surname>Gertz</surname><given-names>BJ</given-names></name><name><surname>Charron</surname><given-names>MJ</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name><name><surname>Moller</surname><given-names>DE</given-names></name></person-group><article-title>Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization</article-title><source>Endocrinology</source><year>2002</year><volume>143</volume><fpage>998</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">11861525</pub-id><pub-id pub-id-type="doi">10.1210/en.143.3.998</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WS</given-names></name><name><surname>Jeng</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>TJ</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>CL</given-names></name><name><surname>Tai</surname><given-names>TY</given-names></name><name><surname>Chuang</surname><given-names>LM</given-names></name></person-group><article-title>Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>376</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">11815513</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naderali</surname><given-names>EK</given-names></name><name><surname>Estadella</surname><given-names>D</given-names></name><name><surname>Rocha</surname><given-names>M</given-names></name><name><surname>Pickavance</surname><given-names>LC</given-names></name><name><surname>Fatani</surname><given-names>S</given-names></name><name><surname>Denis</surname><given-names>RG</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name></person-group><article-title>A fat-enriched, glucose-enriched diet markedly attenuates adiponectin mRNA levels in rat epididymal adipose tissue</article-title><source>Clinical Science</source><year>2003</year><volume>105</volume><fpage>403</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">12780342</pub-id><pub-id pub-id-type="doi">10.1042/CS20030094</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Montague</surname><given-names>CT</given-names></name><name><surname>Prins</surname><given-names>JB</given-names></name><name><surname>Holder</surname><given-names>JC</given-names></name><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>Sanders</surname><given-names>L</given-names></name><name><surname>Digby</surname><given-names>JE</given-names></name><name><surname>Sewter</surname><given-names>CP</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name><name><surname>Chatterjee</surname><given-names>VK</given-names></name><name><surname>O'Rahilly</surname><given-names>S</given-names></name></person-group><article-title>Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation</article-title><source>J Clin Invest</source><year>1997</year><volume>100</volume><fpage>3149</fpage><lpage>3153</lpage><pub-id pub-id-type="pmid">9399962</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kast-Woelbern</surname><given-names>HR</given-names></name><name><surname>Dana</surname><given-names>SL</given-names></name><name><surname>Cesario</surname><given-names>RM</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>de Grandpre</surname><given-names>LY</given-names></name><name><surname>Brooks</surname><given-names>ME</given-names></name><name><surname>Osburn</surname><given-names>DL</given-names></name><name><surname>Reifel-Miller</surname><given-names>A</given-names></name><name><surname>Klausing</surname><given-names>K</given-names></name><name><surname>Leibowitz</surname><given-names>MD</given-names></name></person-group><article-title>Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay ofperoxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis</article-title><source>J Bio Chem</source><year>2004</year><volume>279</volume><fpage>23908</fpage><lpage>23915</lpage><pub-id pub-id-type="pmid">15073165</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M403145200</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tschritter</surname><given-names>O</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Thamer</surname><given-names>C</given-names></name><name><surname>Haap</surname><given-names>M</given-names></name><name><surname>Shirkavand</surname><given-names>F</given-names></name><name><surname>Rahe</surname><given-names>S</given-names></name><name><surname>Staiger</surname><given-names>H</given-names></name><name><surname>Maerker</surname><given-names>E</given-names></name><name><surname>Haring</surname><given-names>H</given-names></name><name><surname>Stumvoll</surname><given-names>M</given-names></name></person-group><article-title>Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">12540592</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>NF</given-names></name><name><surname>Spiegelman</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name></person-group><article-title>Plasma leptin concentrations and four-year weight gain among US men</article-title><source>Int J Obesity</source><year>2001</year><volume>25</volume><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1038/sj.ijo.0801549</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>D</given-names></name><name><surname>Addya</surname><given-names>S</given-names></name><name><surname>Murer</surname><given-names>E</given-names></name><name><surname>Boden</surname><given-names>G</given-names></name></person-group><article-title>15-Deoxy-delta(12,14) prostaglandin J2: a putative endogenous promoter of adipogenesis suppresses the ob gene</article-title><source>Metabolism</source><year>1999</year><volume>48</volume><fpage>786</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">10381155</pub-id><pub-id pub-id-type="doi">10.1016/S0026-0495(99)90180-4</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goetze</surname><given-names>S</given-names></name><name><surname>Bungenstock</surname><given-names>A</given-names></name><name><surname>Czupalla</surname><given-names>C</given-names></name><name><surname>Eilers</surname><given-names>F</given-names></name><name><surname>Stawowy</surname><given-names>P</given-names></name><name><surname>Kintscher</surname><given-names>U</given-names></name><name><surname>Spencer-Hansch</surname><given-names>C</given-names></name><name><surname>Graf</surname><given-names>K</given-names></name><name><surname>Nurnberg</surname><given-names>B</given-names></name><name><surname>Law</surname><given-names>RE</given-names></name><name><surname>Fleck</surname><given-names>E</given-names></name><name><surname>Grafe</surname><given-names>M</given-names></name></person-group><article-title>Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands</article-title><source>Hypertension</source><year>2002</year><volume>40</volume><fpage>748</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">12411472</pub-id><pub-id pub-id-type="doi">10.1161/01.HYP.0000035522.63647.D3</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Lambert</surname><given-names>MH</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name></person-group><article-title>Peroxisome proliferation-activated receptor gamma and metabolic disease</article-title><source>Annu Rev Biochem</source><year>2001</year><volume>70</volume><fpage>341</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">11395411</pub-id><pub-id pub-id-type="doi">10.1146/annurev.biochem.70.1.341</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fiedorek</surname><given-names>FT</given-names></name><name><surname>Wilson</surname><given-names>GG</given-names></name><name><surname>Frith</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Abou-Donia</surname><given-names>M</given-names></name><collab>Study Group-PPA20005</collab></person-group><article-title>Monotherapy with GI262570. a tyrosine-based non-thiazolidinedione PPAR&#x003b3; agonist, improves metabolic control in type 2 diabetes mellitus patients [abstract]</article-title><source>Diabetes</source><year>2000</year><volume>49</volume><fpage>A38</fpage></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Faison</surname><given-names>WL</given-names></name><name><surname>Hashim</surname><given-names>M</given-names></name><name><surname>Harrington</surname><given-names>W</given-names></name><name><surname>Binz</surname><given-names>J</given-names></name><name><surname>Oliver</surname><given-names>W</given-names><suffix>Jr</suffix></name></person-group><article-title>Antidiabetic efficacy of GI262570 in rodent models of type 2 diabetes [abstract]</article-title><source>Diabetes</source><year>2000</year><volume>49</volume><fpage>A278</fpage></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Williams</surname><given-names>CR</given-names></name><name><surname>Risingsong</surname><given-names>R</given-names></name><name><surname>Gilmer</surname><given-names>T</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Sporn</surname><given-names>MB</given-names></name></person-group><article-title>A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW347845, inhibits rat mammary carcinogenesis</article-title><source>Cancer Research</source><year>1999</year><volume>59</volume><fpage>5671</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10582681</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>AC</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name><name><surname>Silvestre</surname><given-names>MJ</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Palinski</surname><given-names>W</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice</article-title><source>J Clin Invest</source><year>2000</year><volume>106</volume><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">10953027</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chirgwin</surname><given-names>JM</given-names></name><name><surname>Przybyla</surname><given-names>AE</given-names></name><name><surname>MacDonald</surname><given-names>RJ</given-names></name><name><surname>Rutter</surname><given-names>WJ</given-names></name></person-group><article-title>Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease</article-title><source>Biochemistry</source><year>1979</year><volume>18</volume><fpage>5294</fpage><lpage>5299</lpage><pub-id pub-id-type="pmid">518835</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bustin</surname><given-names>S</given-names></name></person-group><article-title>Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays</article-title><source>J Mol Endocrinol</source><year>2000</year><volume>25</volume><fpage>169</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">11013345</pub-id></citation></ref></ref-list></back></article> 